The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Medicis Pharmaceutical met expectations on revenue and missed estimates on earnings per share.
Compared to the prior-year quarter, revenue increased and GAAP earnings per share expanded significantly.
Margins grew across the board.
Medicis Pharmaceutical notched revenue of $184.7 million. The 14 analysts polled by S&P Capital IQ predicted a top line of $186.6 million on the same basis. GAAP reported sales were 0.8% lower than the prior-year quarter's $182.1 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $0.56. The 15 earnings estimates compiled by S&P Capital IQ averaged $0.61 per share on the same basis. GAAP EPS of $1.42 for Q3 were 284% higher than the prior-year quarter's $0.37 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 90.5%, 130 basis points better than the prior-year quarter. Operating margin was 31.7%, 620 basis points better than the prior-year quarter. Net margin was 32.6%, 1,950 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $178.7 million. On the bottom line, the average EPS estimate is $0.53.
Next year's average estimate for revenue is $719.3 million. The average EPS estimate is $2.32.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Medicis Pharmaceutical is outperform, with an average price target of $38.00.
The drug and healthcare investing landscape is littered with also-rans and a few major winners. Is Medicis Pharmaceutical the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add Medicis Pharmaceutical to My Watchlist.